Suppr超能文献

通过点击化学快速获得铁霉素衍生物。

Rapid Access to Ironomycin Derivatives by Click Chemistry.

作者信息

Antoszczak Michał, Müller Sebastian, Colombeau Ludovic, Cañeque Tatiana, Rodriguez Raphaël

机构信息

Department of Chemical Biology Institut Curie, CNRS UMR 3666, INSERM U1143, PSL Université 26 rue d'Ulm, 75005 Paris, France.

Department of Medical Chemistry Faculty of Chemistry, Adam Mickiewicz University, Uniwersytetu Poznańskiego 8, 61-614 Poznań, Poland.

出版信息

ACS Org Inorg Au. 2022 Jun 1;2(3):222-228. doi: 10.1021/acsorginorgau.1c00045. Epub 2022 Jan 21.

Abstract

Salinomycin, a natural carboxylic polyether ionophore, shows a very interesting spectrum of biological activities, including selective toxicity toward cancer stem cells (CSCs). Recently, we have developed a C20-propargylamine derivative of salinomycin (ironomycin) that exhibits more potent activity and greater selectivity against breast CSCs compared to the parent natural product. Since ironomycin contains a terminal alkyne motif, it stands out as being an ideal candidate for further functionalization. Using copper-catalyzed azide-alkyne cycloaddition (CuAAC), we synthesized a series of 1,2,3-triazole analogs of ironomycin in good overall yields. The screening of these derivatives against a well-established model of breast CSCs (HMLER CD24/CD44) and its corresponding epithelial counterpart (HMLER CD24/CD44) revealed four new products characterized by higher potency and improved selectivity toward CSCs compared to the reference compound ironomycin. The present study highlights the therapeutic potential of a new class of semisynthetic salinomycin derivatives for targeting selectively the CSC niche and highlights ironomycin as a promising starting material for the development of new anticancer drug candidates.

摘要

沙利霉素是一种天然的羧酸聚醚离子载体,具有非常有趣的生物活性谱,包括对癌症干细胞(CSCs)的选择性毒性。最近,我们开发了一种沙利霉素的C20-炔丙胺衍生物(铁霉素),与母体天然产物相比,它对乳腺CSCs表现出更强的活性和更高的选择性。由于铁霉素含有末端炔基基序,它是进一步功能化的理想候选物。利用铜催化的叠氮化物-炔烃环加成反应(CuAAC),我们以良好的总收率合成了一系列铁霉素的1,2,3-三唑类似物。对这些衍生物针对一个成熟的乳腺CSCs模型(HMLER CD24/CD44)及其相应的上皮对应物(HMLER CD24/CD44)进行筛选,结果显示有四种新产品,与参考化合物铁霉素相比,它们对CSCs具有更高的活性和更好的选择性。本研究突出了一类新型半合成沙利霉素衍生物在选择性靶向CSC生态位方面的治疗潜力,并突出了铁霉素作为开发新型抗癌候选药物的有前景的起始原料。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579d/9955238/94940104052e/gg1c00045_0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验